Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

EGFR Positive Non-small Cell Lung Cancer × pelcitoclax × Thoracic × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 2 EGFR Positive Non-small Cell Lung Cancer 1

Interventions

toripalimab 1 pelcitoclax 1 osimertinib 1 Pemetrexed 1 Paclitaxel 1 Injections 1 Erlotinib Hydrochloride 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04001777 2025-10-01

A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Ascentage Pharma Group Inc.

Phase 1 Active not recruiting

EGFR Positive Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡